Omeros Corporation
Financials
Valuation Metrics
Omeros Corporation's Market Cap is $1.29B. At end of 2025 it was $1.14B. Ranked #2239 of 3,116 in US market (top 72%), #892 of 1,472 on NASDAQ (top 61%), #166 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 63%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.29B | US#2,239/3,116 Sec#166/265 |
| Revenue | $38M | US#2,757/3,116 Sec#152/265 |
| Net Income | $125M | US#1,525/3,116 Sec#52/265 |
| Total Assets | $287M | US#2,908/3,116 Sec#210/265 |
| Net Assets | $-51M | US#2,941/3,116 Sec#245/265 |
| Employees | 175 | US#2,497/3,116 Sec#132/265 |
| Value | ||
| P/E | 10.34x | US#412/3,116 Sec#13/265 |
| P/S | 33.59x | US#2,894/3,116 Sec#159/265 |
| EV/EBITDA | 10.08x | US#901/3,116 Sec#27/265 |
| FCF Yield | -5.33% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | 43.52% | US#14/3,116 Sec#5/265 |
| Op. Margin | -189.53% | US#2,741/3,116 Sec#134/265 |
| Financial Health | ||
| Total Debt | $84M | US#2,476/3,116 Sec#129/265 |
| FCF | $-69M | US#2,572/3,116 Sec#124/265 |
| Cash | $2M | US#3,046/3,116 Sec#264/265 |
| Current Ratio | 1.95x | US#1,265/3,116 Sec#220/265 |
| Net Debt/EBITDA | 0.60x | US#812/3,116 Sec#42/265 |
| Performance | ||
| 1Y Return | 143.25% | US#67/3,116 Sec#22/265 |
| 1M Return | -4.19% | US#2,025/3,116 Sec#134/265 |
| From 52W High | -16.05% | US#910/3,116 Sec#55/265 |
| 1Y MDD | -49.53% | US#2,380/3,116 Sec#155/265 |
| Trading | ||
| Volume | 765,600 shares | US#731/3,116 Sec#63/265 |
| Trading Value | $14M | US#1,339/3,116 Sec#97/265 |
| Per Share | ||
| EPS | $1.72 | US#1,427/3,116 Sec#40/265 |
| BPS | $-0.71 | US—/3,116 Sec—/265 |
Company Info
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.